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Human Hypervariable Sequences in Risk
Assessment: Rare Ha-ras Alleles in Cancer
Patients
by Theodore G. Krontiris,*t Nancy A. DiMartino,t H. David
Mitcheson,§ Joyce A. Lonergan,*t Colin Begg," and David
R. Parkinson*
A variable tandem repeat (VTR) is responsible for the hyperallelism one kilobase 3' to the human
c-Ha-ras-1 (Ha-ras) gene. Thirty-two distinct restriction fragments, comprising 3 allelic classes by fre-
quency ofoccurrence, have thus far been detected in a sample size ofapproximately 800 caucasians. Rare
Ha-ras alleles, 21 in all, are almost exclusively confined to the genomes of cancer patients (p < 0.001).
From our data we have computed the relative cancer risk associated with possession of a rare Ha-ras
allele to be 27.
To understand the molecular basis for this phenomenon, we have begun to clone Ha-ras fragments from
nontumor DNA of cancer patients. We report here the weak activation, as detected by transfection and
transformation ofNIH 3T3 mouse cells, of two Ha-ras genes which were obtained from lymphocyte DNA
ofa melanoma patient. We have mapped the regions that conferthis transformingactivity to the fragment
containing the VTR in one Ha-ras clone and the fragment containing gene coding sequences in the other.
Introduction
Several recent studies have reported that a collection
of rare allelic fragments at the highly polymorphic
c-Ha-ras-1 (Ha-ras) locus appeared only in cancer
patients (1-3). This association has not been obtained
in studies ofpatients with preleukemia (4), lung cancer
(5), ormelanoma (6). In an expanded population survey,
we have now sampled approximately 1600 alleles by
Southern blot analysis of DNA from 424 cancer-free
controls and 369 cancer patients with a wide variety of
tumors. Three groups of fragments (common, inter-
mediate, and rare) have been defined by allelic fre-
quency. We have again observed an increased preva-
lence of rare alleles in cancer patients that is highly
significant (p < 0.001). A family history of cancer in our
controls has no apparent influence on this result. From
these data we have calculated the relative risk of cancer
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in individuals possessing a rare Ha-ras allele to be 27,
which is comparable to the relative risk of cigarette
smoking (7). Since 10% of all cancer patients demon-
strated such alleles, the Ha-ras locus may have general
application in risk assessment.
To understand the molecular basis for the anomalous
population behavior of Ha-ras alleles, we have begun
to clone these genes from the normal tissue of cancer
patients. If rare Ha-ras alleles represent abnormal
genes, we should be able to characterize the defect(s).
Such an outcome would demonstrate rigorously that
inherited lesionsofoncogenesoccurthatareresponsible
for an increased lifetime riskofdeveloping cancer. Fur-
thermore, wecouldthenexploitthisknowledgetorefine
strategies forpredictingrisk. We report here ourinitial
investigation ofthe transforming activity possessed by
Ha-ras genes cloned from the lymphocytes ofa familial
melanoma patient.
Material and Methods
Study Population
Asbefore, ourstudypopulationconsistedofunrelated
caucasians with and without cancer. The tumors were
carcinomas of the head and neck (approximately 1% of
cases); lung (5%); breast (16%); gastrointestinal tract
(5%), including esophagus, stomach, pancreas, liver,KRONTIRIS ET AL.
(5%), includingesophagus, stomach, pancreas, liver, co-
lorectum; genitourinary tract (22%), including kidney,
bladder, prostate, testis; and female reproductive tract
(8%), including ovary, uterus, cervix, endometrium; as
well as lymphoma (18%); melanoma (4%); sarcoma (2%);
and myeloma (1%). Acute and chronic leukemia, oflym-
phocytic and nonlymphocytic origin, accounted for 11%;
brain tumors accounted for 2%, nonmelanoma skin can-
cers for 3%, and tumors of unknown primary for 2%.
Thirty ethnic/nationality groups were equally repre-
sented in both the cancer and control populations. We
have shown that the distribution ofrare alleles was not
influenced bythisfactor, since thefractionofrare alleles
contributed by any one ethnic group was proportional
to the representation of that group in cancer patients
(2). In this study we have expanded the data from can-
cer-free controls toinclude those with apositive history
of cancer in first degree relatives.
Ha-ras Genotype Determination
Leukocyte and tumor DNAs were prepared and di-
gested with MspI/HpaII as previously described (1,2).
Samples were subjected to electrophoresis through
0.7% agarose gels. Southern transfer (8), hybridization
to Ha-ras probe, washing, and autoradiography were
performed as before (1,2). Fragment sizes were deter-
mined by coeletrophoresis of HindIII-digested lambda
DNA, and al, a2, a3, and a4 markers (the four most
common Ha-ras alleles) on each gel. After this prelim-
inary electrophoresis, a putative new allele was run
against previous isolates of similar size. This process
confirmed the existence ofa new allele and, at the same
time, allowed therelative ordering ofall the allelicfrag-
ments, even though the determination of fragment
length was only reproducible to ± 50 bp. Thus, frag-
ment lengths given below represent interpolations.
Cloning of Ha-ras Alleles
DNA was purified from EBV-transformed lympho-
cytes ofapatient with familial melanoma (1). Following
digestion with BamHI, the DNA was ligated into the
BamHI site of the lambdoid bacteriophage, L47.1 (9)
and packaged using a commercial extract (Gigapack,
Stratagene). Recombinant phage was plated on a P2
lysogen, and plaques were screened directly by the
method ofBenton and Davis (10).'The BamHI fragment
ofHa-rasfromtheplasmidpEC (11)-wasnick-translated
(12) for probe.
DNA Transfection
For direct transfection, a precipitate of 1000 ng of
plasmid DNAcontainingthepatient's Ha-rasfragments
and 20 ,ug ofcarrier NIH 3T3 DNA was applied to 5 x
105 NIH 3T3 cells in a 60-mm tissue culture dish follow-
ing the method of Graham and van der Eb (13). pEJ
(33.3 ng), which contained the activated Ha-ras gene
fromthe EJbladdercarcinomacellline (14), wasapplied
with carrier as a positive control. Cotransfection ofHa-
ras clones and pSV2neo (15) was performed as follows:
0.8 ,ug of pSV2neo + 1 pug of an Ha-ras plasmid were
coprecipitated asaboveandincubatedwith5 x 105NIH
3T3 cells per 60-mm dish. Two days after transfection,
selection with the antibiotic G418 (Geneticin, GIBCO),
at 400 ,ug/mL, was begun. Ten days after transfection,
each plate was trypsinized and the cells transferred to
a 100-mm tissue culture dish. Two to three weeks after
transfection, the proportion of transformed cells (fusi-
form, refractile morphology) was noted.
Construction of Ha-ras Chimers
The patient's two allelic fragments, al and a2.1, were
subclonedintotheBamHI siteofpBR322. Theresulting
plasmids were designated pGDal and pGDa2.1, re-
spectively. For the construction of chimeric clones in-
volving various fragments of pGDal, pGDa2.1, pEC,
and pEJ, plasmids were digested with NotI, which re-
leased a 2.5-kb fragment containing the four coding ex-
ons. The NotI fragment was exchanged among the dif-
Table 1. Ha-ras allelic frequencies.a
Allele
al
a2
a3
a4
al.2
al.1
a4.1
aO.1
al.3
al.4
a5
a3.2*
a2.2*
a2.3
a2.4
a3.1*
a3.3*
a3.4*
al.35*
a2.01*
a3.5*
a4.2*
aO.15*
aO.2*
al.25*
a2.015*
a2.02*
a2.025*
a2.1*
a2.11*
a2.12*
a5.2*
Detected in
family
member
Yes
Yes
Yes
Yes
Yes
Yes
Yes
MspI/HpaII
size (bp)
1000
1500
2160
2560
1110
1060
2610
980
1230
1450
2800
Yes 2280
Yes 1820
Yes 1880
2100
Yes 2220
Yes 2330
2410
1280
1560
2480
2710
880
Yes 810
1180
1590
1650
1680
Yes 1710
1750
1790
3080
No. d
Total 15
letected Frequency
975 0.612
192 0.121
154 0.097
140 0.088
34 0.021
16 0.010
11 0.007
8 0.005
8 0.005
7 0.004
7 0.004
4 0.002
3 0.002
3 0.002
3 0.002
3 0.002
3 0.002
3 0.002
2 0.001
2 0.001
2 0.001
2 0.001
1 0.0006
1 0.0006
1 0.0006
1 0.0006
1 0.0006
1 0.0006
1 0.0006
1 0.0006
1 0.0006
1 0.0006
92
aTo accommodate the new intermediate-frequency allele, al.4, the
cancer-associated rareallele, previouslycalled al.4, wasreassignedthe
designation al.35. Rare alleles were detected in patients' first degree
relatives in the nine instances in which family members were available
for testing (seven rare alleles). Asterisks denote alleles found only in
cancer patients.
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FIGURE 1. Resolution of Ha-ras allelic fragments. WBC DNAs were digested with MspI/HpaII (A, B, and C) or PstI (D), blotted and
hybridized to Ha-ras probe. Bars in B and C represent the migration ofmarkers; dotted line is the migration of patients' intermediate or
rare alleles. (A) Rare aO.2 and a2.3 alleles in two members of a melanoma kindred (lanes 1 and 2). M is a marker DNA with a3 and a4
alleles. Migration of al and a2 alleles, from another gel lane not included in the photo, is also indicated. (B) M is a marker DNA with al
and a2 alleles; S is TCC patient WBC DNA with al.4 allele. (C) M is a marker DNA with a3 and a4 alleles; S is TCC patient WBC DNA
with a3.5 allele. (D) PstI confirmatory digest. M is marker DNA with al and al.2 alleles. Si and S2 are WBC DNA samples from two TCC
patients with al.2 alleles by MspI/HpaIII.
to determine the influence ofcoding sequences on trans-
forming activity ofthe patient clones. To determine the
influence ofthe VTR, the SphI fragmentcontainingthis
structure was exchanged. Finally, to differentiate the
influence of coding exons 1/2 versus exons 3/4, NcoI/
BglII fragments were exchanged (see "Results" and
Fig. 2).
Results
VTR Polymorphism at the Ha-ras Locus
The remarkable degree of hyperallelism at the Ha-
ras locus is evident, as shown in Table 1. Thirty-two
fragments, inthree allelic classesbyfrequencyofoccur-
rence, have been detected thus far. Aspreviously noted
(1,2), Ha-ras polymorphism is generated by the varia-
tion of a tandemly repetitive sequence, designated the
VTR, 3' to the gene coding exons. For the most part,
rare alleles are easily distinguished from their common
counterparts (Fig. 1A). However, very minor varia-
tions, or microheterogeneity, can be reproducibly dem-
onstrated with the appropriate technical precautions
(Fig. 1B,C) (2). The isoschizomers MspI/HpaII, which
produce the greatest resolution of polymorphic frag-
ments, are required; several other enzymes, AvaI (4),
PvuII (5), and BamHI (16), produce successively larger
fragments and are correspondingly insensitive. [Any of
these enzymes, orPstI, canbeused toconfinnthat rare
alleles are not the result of partial digestion with, or
site polymorphism of, MspI/HpaII (Fig. 1D).] Since
minor differences in salt concentration of electrop-
horesed samples can produce artifactual migration dif-
ferences, internal migration controls, such as those
denoted by the solid bands in panels B and C ofFigure
1, are required. Mixing ofDNA samples and coelectro-
phoresis can be performed, although this is not usually
necessary because informative internal control bands
are nearly always present in the samples being tested.
Finally, sample DNA concentrations are carefully mon-
itored, since both overloading and inequality between
samples generate irreproducible variation (4).
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FIGURE 2. Restriction map ofthe Ha-ras gene. The solid line denotes Ha-ras DNA and the stippled line, pBR322. Open boxes are noncoding
exons; solid boxes are the four translated exons. The box with vertical stripes is the VTR. The gap within it indicates that the size is
variable (from 800-3100 bp). B, BamHI, N, NotI, Nc, NcoI, S, SphI, Bg, BglII.
Rare Ha-ras Alleles Occur Nearly
Exclusively in Cancer Patients
The distribution of Ha-ras allelic classes in cancer
patients and cancer-free controls is shown in Table 2.
Rare alleles are almost exclusively confined to cancer
patients. Thus far, only a2.3 has occurred in a normal
control with a negative family history of cancer. Ofnote
is the finding that even cancer-free individuals with a
positive family history have demonstrated but one rare
allele, a2.4. At a comparable stage ofcollection, cancer
patients had already accounted for more than 20 rare
alleles (2). The distribution of alleles is highly statisti-
cally significant by chi-square analysis (6 df). The rel-
ative risk ofpossessing a rare allele is 27 (pooling pos-
itive and negative family history groups) or36 (controls
without family history of cancer).
Distribution of Ha-ras Alleles in Bladder
Cancer Patients
Inthe population-at-large, intermediate frequency al-
leles are not associated with cancer to a statistically
significant degree. Within particular subgroups, how-
ever, patterns may vary. Most of the unusual Ha-ras
alleles we detected in a small group ofmyelodysplastics
(1) have proved to be of intermediate frequency. As
more of these patients were accumulated, the associa-
tion of Ha-ras alleles with disease has not been main-
tained (4 and unpublished observations). Interestingly,
several of these myelodysplastics who progressed to
Table 2. Distribution of Ha-ras allelic subgroups in normal
individuals and cancer patients.a
Common Intermediate Rare
DNA source (al-a4) (al.2-a.5) (a3.2-a5.2) Total
Cancer patient WBC 481 38 31 550
Cancer-free WBC
Family history
negative 540 33 1 574
Family history
positive 266 7 1 274
Patient tumors 174 13 7 194
aThe distribution ofalleles inWBC and tumor DNAs is statistically
significant (chi-square, 6 df) to p < 0.001. The rare allele in the family-
history-negative group is a2.3; in the family-history-positive group,
a2.4.
frank leukemia had rare alleles (1). Therefore, rare Ha-
ras alleles, when they occur in myelodysplasia, may
predict the eventual appearance of malignant disease.
In certain tumor groups, however, the association of
intermediate frequency alleles with cancer was
stronger. Judging from the reported fragment sizes,
many ofthe unusual Ha-ras alleles detected in a breast
cancer study (3) were in the intermediate frequency
class. Intransitional cell carcinoma ofthe genitourinary
tract (Table 3), intermediate alleles appearnearly three
times more frequently (16.4%) than the total population
(5.7%) and more than twice as often as the control
groups with other types ofgenitourinary cancer or be-
nign genitourinary disease (p = 0.02). These results
indicate that each tumor type must eventually be ex-
amined separately for association with rare and inter-
mediate Ha-ras alleles.
Analysis of a Unique Ha-ras Allele by
Molecular Cloning
We have cloned BamHI fragments containingthe Ha-
ras transcriptional controls, coding sequences, and var-
iable tandem repeat from the normal DNA of a mela-
noma patient belongingto a kindred with the dysplastic
Table 3. Ha-ras alleles in genitourinary (GU) malignancy.a
WBC DNA from
patients with Common Intermediate Rare
Transitional cell cancer (61) 96 20 6
Other GU malignancy (42) 77 4 3
Benign GU disease (35) 65 5 0
aLeukocyte (WBC) DNA from peripheral blood of patients with
transitional cell carcinoma (TCC; two from the kidney, the remainder
bladder), other GU malignancy (prostate, renal, and testicular) and
benign conditions ofthe GU tract (prostatic hypertrophy, infections,
infertility, impotence and renal calculi) were prepared and blotted as
described inTable 1. Numbersinparentheses representtotalpatients
in each group. Allintermediate alleles were detected inTCC patients;
only al.1 and al.2 were detected in the othertwo groups. Rare alleles
in TCC patients were a2.4, a3.4, a3.5, and a5.2. Rare alleles in other
GU tumorpatients were a2.01, a2.2, and a3.4. The proportion ofrare
alleles ineachcategoryconformsroughlytothatexpectedfromTables
1 and 2. Statistical significance of the distribution of intermediate
alleles (p = 0.02) was computed by chi-square analysis from the 2 by
3tableinwhichcommon + rarealleles werecomparedtointermediate
alleles in each ofthe three patient groups.
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nevus syndrome and cutaneous melanoma (1). The pa-
tient's brother had melanoma, and a niece presented
with metastatic ovarian carcinoma at age 22. All these
individuals share an Ha-ras fragment that is unique to
the family. From DNA of EBV-transformed lympho-
cytes ofthe patient, GD, we have obtained his common
al allele, as well as the unique a2.1 allele (see Table 1).
The BamHI fragments have been subcloned into
pBR322 and have been designatedpGDal and pGDa2.1,
respectively. Our structural characterization of these
nontumor clones thus far has localized the major dif-
ference between them to the VTR, as expected. Fur-
thermore, fine structure mapping with purified VTRs
from both clones indicates that the entire region is com-
posed of 28 bp tandem repeats. Consequently, at this
level ofresolution, no DNA has been inserted or trans-
posed into the VTR (data not shown).
Transforming Activity of Patient's Ha-ras
Genes
Activation ofras protooncogenes in tumors occurs by
the frequent mutation of codons 12 and 61 (17). Other
mutations, as well as changes which augment transcrip-
tion, can activate Ha-ras (17), although the phenotype
in these cases is usually far less dramatic than that of
12/61 mutations. When ras genes are activated, they
become capable of tumorigenic transformation of
growth-regulated cell lines, and the immortalization of
normal diploid cell strains (17). Therefore, we wished
to determine if the Ha-ras genes we had cloned from
normal tissue of the melanoma patient demonstrated
any evidence of lesions which could activate the pro-
tooncogene.
Tothisend, theplasmidsubclonescontainingthecom-
mon and unique Ha-ras fragments ofthe melanoma pa-
tient were used to transfect NIH 3T3 cells. In the stan-
dard assay, 3 ,ug plasmid DNA + 60 ptg carrier is pre-
cipitated and incubated with cells in three 60-mm cul-
ture dishes; 500,000 cells per dish. The dishes are
incubated for2 weeks and transformed foci are counted.
Under such conditions, neither patient clone trans-
formed NIH 3T3 cells (Table 4).
For further studies on spontaneous and induced
transformation of cells bearing al and a2.1 fragments,
the same subelones were cotransfected with aselectable
marker, pSV2neo (1.7 ,ug neo + 2.0 ,ug ras clone +
36.3 jig carrier precipitated and incubated with cells
from two 60-mm dishes). Plates transfected only with
pSV2neo were also included. In this way, we intended
to introduce the apparently phenotypically "silent" pa-
tient genes into NIH 3T3 cells as passengers with
pSV2neo, which conferred resistance to the antibiotic
Table 4. Direct transfection of patient Ha-ras clones.
Ha-ras DNA Total foci/no. plates
pEJ 575/3
pGDal 0/3
pGDa2.1 0/3
Table 5. Cotransfection with pSV2neo.
After cell transfer
Primary transfectants Plates
Ha-ras Colonies/ Colonies transformed/ Extent of
DNA plate transformed total plates transformation
None 335 None 0/2 0
pGDal 410 None 2/2 1 +
pDGa2.1 300 None 2/2 2+
a 1 + = 25% transformed; 2+ = 50% transformed.
Table 6. Cotransfection with pSV2neo and pEC.
After cell transfer
Primary transfectants Plates
Ha-ras Colonies/ Colonies transformed/ Extent of
DNA plate transformed total plates transformationa
None 350-400 None 0/2 0
pEC 350-400 None 0/2 0
pGDal 350-400 None 2/2 2+
pGDa2.1 350-400 None 2/2 2+
a2+ = 50% transformed.
G418. When resistant colonies of NIH 3T3 cells first
appeared (50-100 cell stage), the plates were trypsin-
ized. Cells were replated at limiting dilution to obtain
cell clones that were resistant to G418 and, potentially,
contained one or a few copies of either al or a2.1. We
subsequently have checked by Southern blotting of
DNA from the cloned NIH 3T3 sublines that this co-
transfer did indeed occur. At the same time, the re-
mainderofthecells fromthistransfectionwerereplated
and allowed to become confluent.
The results of this first cotransfection are presented
in Table 5. Although cells transfected only with
pSV2neo remained flat, 25 to 50% of cells transfected
with either the common al or unique a2.1 fragment
became transformed under the conditions ofthe assay.
This level of transformation represented a relatively
high frequency event and should not be viewed as the
simple comparison of 0/2 and 2/2 events. We have two
independent confirmations of this assertion. First, all
10 NIH 3T3 subclones we have examined by Southern
blotting (5 of which are transformed) are independent
transfectants. No common bands are observed except
for the expected 2.9-kb SacI fragment containing Ha-
ras coding sequences (data not shown). Second, several
subclones were chosen because their originating -Iolo-
nies from limiting dilution were flat. These were main-
tained by passaging at subconfluence until Southern
blotting confirmed one to two copies ofal or a2.1. Then
10,000 cells from each of three sublines (neo only, neo
+ al andneo + a2.1)wereplatedandallowedtobecome
confluent. At 2 weeks, both the al- and a2.1-containing
clones had several hundred transformed foci per plate.
The neo control demonstrated none. Thus, cell clones
bearing either of the patient's Ha-ras genes exhibited
high frequency spontaneous transformation.
Because the normal Ha-ras gene will transform NIH
3T3 cells at low efficiency if gene expression is aug-
mented by increased transcription or gene amplifica-
tion, we wishedtorule outthepossibility that ourresult
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was simply the artifactual activation of normal Ha-ras
clones. This seemedunlikely, sincethe amount ofcloned
Ha-ras DNA required to produce this effect is more
than an order of magnitude greater than that of our
protocol. Also, severaltransformants donothaveampli-
fied Ha-ras by Southern blot analysis. However, the
pSV2neo we employed contains the SV40 enhancer, so
it was possible that increased transcription was
obtained by the cotransfection. Therefore, we repeated
the experiment described above with two changes.
First, nolimitingdilutionwasperformedbecauseclones
were not desired. Second, another cotransfection pair
was added: pSV2neo + the nontransforming Ha-ras
protooncogene, pEC. This plasmid is a normal Ha-ras
BamHI fragment cloned into pBR322. Once again,
cotransfection of al and a2.1 led to transformation of
NIH 3T3 cells (Table 6). Cells from both the pSV2neo
control and the cotransfection involving the protoon-
cogene clone pEC remained untransformed. Therefore,
the transformation phenomenon was specific to clones
from the patient. Since these clones were obtained from
his lymphocyte DNA, not his tumor DNA, we have
isolated Ha-ras genes bearing potentially inherited
lesions. This result, including transfection with pEC,
has now been reproduced in multiple experiments.
Mapping the Regions Responsible for
Transforming Activity in pGDal and
pGDa2.1
Finally, we haveconstructed aseriesofchimericplas-
mids in which the coding sequences, promoter/exon
(- 1) and VTR ofa2.1, al, and pEC have been recom-
bined. These exchanges have allowed us to map the
region of each Ha-ras clone responsible for the trans-
forming activity detected by cotransfection. In this set
ofexperiments, each chimerwas transfected directly or
cotransfected withpSV2neo. pEC controls were always
present. The results to date are summarized in Table
7. Thetransforming activity ofa2.1 residedinthe VTR-
containing fragment. For al, the relevant region was
the coding sequences, particularly the fragment con-
taining exons 3 and 4. For al, an unusual coding
sequence mutation may, therefore, exist. The con-
structs involving pEC indicated that all regions ofthis
clone may be activated by the appropriate regions ofal
and a2.1. Hence, our negative control was not artifac-
tually inactive in these assays as the result of some
unknown lesion we introduced during, say, pEC DNA
purification. Additional information from the chimer
experiments was the finding that the a2.1 VTR was
active in both orientations, suggesting an enhancerlike
function.
Discussion
The basis for the association we have detected, rare
Ha-ras alleles in cancer patients, remains obscure. Dis-
Table 7. Chimer transfections.a
Promotor/ Coding Transforming activityb
exon (-1) sequences VTR Direct Cotransfection
Exchanges ofBamHI-NotI, NotI-NotI, and NotI-BamHI fragments
EJ
EC
a2.1
al
al
alc
EC
a2.1
a2.1
EJ
EC
a2.1
al
a2.1
a2.1
al
EC
al
EJ
EC
a2.1
al
al
a2.1
EC
a2.1
a2.1
3-4+
0
4+
0
0 2+
0 1-2+
o o
0 2-3+
0 2+
0 3+
0 2-3+
Exchanges of SphI fragments, which involve only the VTR
EC
ECd
EC a2.1
EC a2.1
ND 2-3+
ND 2-3+
Exchange of NcoI-BglII fragments, which result in the separation
of exons 1/2 from exons 3/4
EC EC(1/2) al(3/4) al ND 2-3+
al al(1/2) EC(3/4) EC ND 0-1+
aTransfections were performed as described in the text. pEC nega-
tive control was included in each set of assays (a total of six separate
experiments).
b0 = no transformed cells; 1 + = 25% transformed; 2+ = 50%
transformed; 3 + = 75% transformed; 4 + = 100% transformed;
ND = not done.
eSphI fragment containing the a2.1 VTR was exchanged for the al
VTR in the chimer al/a2.1/al.
dDenotes a clone in which the orientation of the VTR has been
reversed.
tinct underlying mechanisms may be responsible in dif-
ferent tumors. We have observed segregation of the
disease locus and Ha-ras in a Von Hippel Lindau
kindred (2andunpublished observations) andinfamilies
with the dysplastic nevus syndrome/melanoma or fam-
ilial melanoma (T.G.K. and S.J. Bale, National Cancer
Institute, unpublished; 6). Nevertheless, in 19suchmel-
anoma families, we have detected 7 rare alleles (Fig. 1)
(1). This would imply that tandem repeat instability,
not Ha-ras, demonstrates the principal association with
familial melanoma. Such instability may secondarily
affect Ha-ras genes: As we have reported, both the
commonand unique Ha-ras fragments fromlymphocyte
DNA ofa familial melanoma patient demonstrate weak
transforming activity in NIH 3T3 cells.
Whether similar results will be obtained in sporadic
cancer cases remains to be determined. IfHa-ras genes
linked torareVTRs accelerate tumorprogression, then
linkage should eventually be detected in sporadic can-
cer. Ifan entirely distinct mechanism, genetic instabil-
ity leading to the increased frequency ofappearance of
rare VTRs, is the basis for our observations, then one
might expect an increased rate of appearance of new
alleles at VTR loci distinct from Ha-ras. Although such
did not occurat a VTR locus we have studied on chrom-
some 10 (2), other hypervariable region probes may
prove more informative. Since nontumor Ha-ras clones
from the familial melanoma patient display weak acti-
vation, despite lack of Ha-ras linkage to the melanoma
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gene even within this kindred, we have hypothesized
that Ha-ras genes upstream from their unstable VTR
element may suffer "innocent bystander" lesions during
the generation of new VTRs or recombination within/
nearby common VTRs (as with our al clone). Alter-
natively, the creation ofa new VTR may be associated
with some effect on Ha-ras expression, such as mRNA
stabilization or transcriptional enhancement (as with
our a2.1 clone). In sporadic cancer, where no familial
disease locus predominates, such lesions maybe central
to the governance ofgenetic risk. Further investigation
of patient Ha-ras clones, combined with a population
analysis oftandem repeats throughout the human gen-
ome, should clarify these issues.
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